University of Birmingham Enterprise announces the formation of a new spinout company, Viatem Ltd, to develop and exploit the therapeutic potential of PEPITEM (Peptide Inhibitor of Trans-Endothelial Migration)
The announcement coincides with the presentation of new research showing that synthetic PEPITEM can prevent or delay the onset of rheumatoid arthritis (RA) in animal models of disease and restore regulation of white blood cell migration in human tissues1.
RA is an autoimmune disease that affects over 20 million people worldwide2. It results in extensive damage to joints and causes significant disability. Currently there is no curative treatment.
PEPITEM is a 14 amino acid peptide, and a naturally occurring mediator in the adiponectin pathway which controls the recruitment of immune cells into inflamed tissues. The pathway was discovered by researchers at the Institute of Cardiovascular Sciences at the University of Birmingham and described in their seminal paper in Nature Medicine in 20153.
An illustration of the pathway which modulates the migration of T-cells (white blood cells) from the blood stream into body tissues
The adiponectin pathway is believed to be pivotal in protecting inflamed tissues from excessive damage, and is disordered in conditions such as rheumatoid arthritis, inflammatory bowel disease and type 1 diabetes, all of which are characterised by chronic inflammation that destroys the patient’s own tissues.
According to Dr Jonathan Watkins, Head of IP at University of Birmingham Enterprise, it was the foundational nature of the science that first attracted the attention of the University’s technology transfer and commercialisation teams.
It is extremely rare that a completely new regulatory pathway is discovered and that it is possible to modulate it through an identified target” said Dr Watkins.
Dr James Wilkie, CEO of University of Birmingham Enterprise, commented: “Despite substantial innovation over the last few decades, there are still significant unmet needs in rheumatoid arthritis treatment. We are delighted to be commercialising this novel therapeutic target which is supported by a robust and increasing body of evidence.”
The new research, presented at the Latin-American Association of Immunology in Cancun, Mexico showed the administration of synthetic PEPITEM:
The University has licensed the technology to the newly formed spinout company Viatem Ltd. The University is a shareholder in the company, which has received funding from Innovate UK, the West Midlands Academic Health Science Network and the University of Birmingham’s Enterprising Birmingham Fund.
Viatem is located in the BioHub Birmingham, the University’s bioincubator, which is based at the Birmingham Research Park.
The researchers will be presenting further data at EULAR 2018.